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Abstract
Progressive reduction in kidney function in patients following myocardial
infarction (MI) is associated with an increase in circulating uremic toxins lev-
els leading to increased extracellular matrix deposition. We have recently
reported that treatment with uremic toxin adsorbent AST-120 in rats with MI
inhibits serum levels of uremic toxin indoxyl sulfate (IS) and downregulates
expression of cardiac profibrotic cytokine transforming growth factor beta
(TGF-b1). In this study, we examined the effect of uremic toxins post-MI on
cardiac microRNA-21 and microRNA-29b expression, and also the regulation
of target genes and matrix remodeling proteins involved in TGFb1 and angio-
tensin II signaling pathways. Sixteen weeks after MI, cardiac tissues were
assessed for pathological and molecular changes. The percentage area of car-
diac fibrosis was 4.67  0.17 in vehicle-treated MI, 2.9  0.26 in sham, and
3.32  0.38 in AST-120-treated MI, group of rats. Compared to sham group,
we found a twofold increase in the cardiac expression of microRNA-21 and
0.5-fold decrease in microRNA-29b in heart tissue from vehicle-treated MI.
Treatment with AST-120 lowered serum IS levels and attenuated both, cardiac
fibrosis and changes in expression of these microRNAs observed after MI. We
also found increased mRNA expression of angiotensin-converting enzyme
(ACE) and angiotensin receptor 1a (Agtr1a) in cardiac tissue collected from
MI rats. Treatment with AST-120 attenuated both, expression of ACE and
Agtr1a mRNA. Exposure of rat cardiac fibroblasts to IS upregulated angioten-
sin II signaling and altered the expression of both microRNA-21 and micro-
RNA-29b. These results collectively suggest a clear role of IS in altering
microRNA-21 and microRNA-29b in MI heart, via a mechanism involving
angiotensin signaling pathway, which leads to cardiac fibrosis.
Introduction
Kidney dysfunction is a common consequence of myocar-
dial infarction (MI), and results in a greater risk of in-
hospital death and cardiovascular events such as heart
failure and stroke (Anavekar et al. 2004; Goldberg et al.
2005, 2009; Parikh et al. 2008). We have recently demon-
strated that elevated serum uremic toxins levels, such
as indoxyl sulfate (IS), lead to a progressive decline in
kidney function as well as increased levels of cardiac
TGF-b1 and collagen protein in rat model of MI (Le-
kawanvijit et al. 2013). Indoxyl sulfate is a small nondia-
lyzable protein-bound uremic toxin derived from dietary
tryptophan. It is metabolized by the gut microflora to the
precursor indole where it is absorbed across the gastroin-
testinal tract prior to its conjugation to IS by the liver
(Lekawanvijit et al. 2012b). AST-120 is an inert carbon-
based oral adsorbent that has been used clinically to bind
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indole in the gut preventing its absorption into the circu-
lation (Aoyama and Niwa 2001). Lowering uremic toxin
levels in MI rats using the oral adsorbent AST-120,
reduced cardiac expression of collagen I protein and
transforming growth factor (TGF-b1) (Lekawanvijit et al.
2013). However, the molecular mechanisms involved in
post-MI IS-mediated upregulation of TGF-b1 and fibrosis
is not known.
MicroRNAs are small endogenously transcribed regula-
tory RNA that modulates gene expression by binding to
either 30 or 50 untranslated regions (UTR) of mRNA or
promoter sequences. These master regulators of cell
homeostasis are known to regulate many cardiac pro-
cesses and play a role in cardiac dysfunction (Thum et al.
2008; Qin et al. 2011; Salic and De Windt 2012). MicroR-
NA-21 and microRNA-29 are among the most abun-
dantly expressed microRNAs in heart and are known to
regulate fibrosis by their action on mRNA of extracellular
matrix proteins and TGF-b1 (van Rooij et al. 2008; Liang
et al. 2012). MicroRNA-21 has an inhibitory effect on
sprouty 1 (Spry1), phosphatase and tensin homolog
(PTEN) and Smad 7, all known to suppress the TGF-b1
signaling pathway (Zhang et al. 2007; Thum et al. 2008;
Roy et al. 2009; Adam et al. 2012; Li et al. 2013), there-
fore increases in microRNA-21 may lead to an upregula-
tion of TGF-b1 signaling. TGF-b1, collagen 1A1 and
fibronectin-1 are direct targets of microRNA-29b, hence
an increase in microRNA-29b may lead to inhibition of
TGF-b1 signaling (Wang et al. 2012; Xiao et al. 2012;
Zhang et al. 2014).
Angiotensin II has been shown to activate Smad path-
ways via TGF-b-dependent (Sorescu 2006; Huang et al.
2010) and -independent mechanisms (Rodriguez-Vita
et al. 2005; Rodrigues Diez et al. 2010). Treatment of car-
diac fibroblast cells with angiotensin II increased expres-
sion of TGF-b1, microRNA-21 but inhibited expression
of microRNA-29b (Zhang et al. 2014). Earlier studies
have reported involvement of the angiotensin type 1
receptor (Agtr1) in angiotensin II-mediated upregulation
of TGF-b1 expression in cardiac myocytes and fibroblasts
(Rosenkranz 2004). However, the effect of IS on cardiac
angiotensin II signaling in the MI heart is not known.
Also, an important question, whether the uremic toxin IS
promotes myocardial fibrosis by altering cardiac TGFb1-
microRNA-21 and/or TGFb1-microRNA-29b signaling
remains unexplored.
This study is the first to examine the role of uremic
toxins post-MI on cardiac microRNA-21 and microRNA-
29b expression, and examine the regulation of target
genes and matrix remodeling proteins involved in TGFb1
and angiotensin II signaling pathways. In vitro studies
using cardiac fibroblast cells will confirm the direct effects
of IS on these microRNAs and target gene expression.
Materials and Methods
Animals
Male Sprague–Dawley rats (220–250 g) underwent left
anterior descending (LAD) ligation to induce myocardial
infarction (MI) by methods described earlier (Rana et al.
2010; Dworak et al. 2012; Kompa et al. 2013). Briefly,
animals were intubated and artificially ventilated with 2%
isoflurane in oxygen. A left thoracotomy was performed
and the LAD coronary artery ligated with a 6–0 prolene
suture a 2–3 mm below its origin. Visible blanching and
hypokinesis of the anterior LV wall were indicative of
successful ligation. A sham operation involved the same
procedure except the LAD was not ligated. The thorax
was then closed after briefly inflating the lungs to expel
air from the thoracic cavity, and the skin was sutured. On
recovery, MI animals were randomized to receive either
AST-120 (MI+AST-120, n = 9) or no treatment
(MI+vehicle, n = 8) for 16 weeks. AST-120 (Kremezin,
Kureha Pharmaceuticals, Tokyo, Japan) was administrated
postoperatively in the chow at 8% w/w with unrestricted
access. Sham-operated rats (n = 12) were used as con-
trols.
Serum IS levels were measured using high-performance
liquid chromatography method (Shimadzu, Kyoto, Japan)
at study endpoint (16 weeks post-MI). In the final week
of the respective study, echocardiography performed for
assessment of cardiac function, and blood pressure mea-
surements recorded prior to tissue harvest. Tissues were
assessed for changes in gene expression using real-time
PCR. The investigation conformed to the Guide for the
Care and Use of Laboratory Animals published by the US
National Institutes of Health (PHS Approved Animal
Welfare Assurance No. A5587-01). All animal usage was
also approved by the St Vincent’s Hospital’s Animal Eth-
ics Committee (AEC) in accordance with the National
Health and Medical Research Council (NHMRC) guide
for the care and use of laboratory animals.
Cardiac function assessment –
echocardiography and hemodynamic
measurements
Echocardiography was performed in lightly anesthetized
animals (ketamine 40 mg/kg, xylazine 5 mg/kg, i.p.) using
a Vivid 7 (GE Vingmed, Horten, Norway) echocardiogra-
phy machine with a 10 MHz phased array probe. The
procedure was performed as per published protocol rou-
tinely used in our laboratory (Rana et al. 2010; Kompa
et al. 2013). For hemodynamic assessment, animals were
intubated, and under positive pressure ventilation, a
micromanometer (Millar Instruments, Houston TX) was
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inserted into the right common carotid artery for measur-
ing blood pressure and heart rate, recorded on a Powerlab
using Chart (v5) software (ADInstruments, Bella Vista,
NSW, Australia).
Glomerular filtration rate (GFR)
One day prior to sacrifice, GFR was performed to mea-
sure kidney function. Briefly, animals were injected with
0.26 mL (i.v.) of the radioactive isotope, 99technetium-di-
ethylene triamine penta-acetic acid (99Tc-DTPA) prepared
at a rate of 37 MBq/ml (1 mCi/mL). Animals were bled
43 min later and their plasma radioactivity measured and
compared to the counts of the standard reference pre-
pared at the time of injection. GFR/kg body weight was
calculated as described in previous studies published by
our group (Kelly et al. 1998; Lekawanvijit et al. 2012a).
Neonatal rat cardiac fibroblast culture and
treatment
We used isolated neonatal rat cardiac fibroblasts (NCF)
in our study to investigate direct effects of indoxyl sulfate
on cardiac cells on expression genes and microRNAs
involved in cardiac fibrosis during cardiac remodeling.
NCF were isolated from 1- to 2-day-old pups with enzy-
matic digestion as described in detail previously (Simpson
1985; Woodcock et al. 2002). All animal usage was also
approved by AMREP Animal Ethics Committee (AEC) in
accordance with the National Health and Medical
Research Council (NHMRC) guide for the care and use
of laboratory animals (E/0980/2010/M). NCF were seeded
and maintained in high-glucose (25 mmol/L) DMEM
(Invitrogen, Mount Waverley, Vic, Australia) in the pres-
ence of 1% antibiotic/antimycotic (Invitrogen) and 10%
FBS (JRH biosciences). NCF were used at passage 2 (See
et al. 2004; Lekawanvijit et al. 2010). NCF were then
seeded at a density of 250,000 cells/well in 6-well plates
and incubated (5% CO2) overnight before serum starved
with 0.5% bovine serum albumin (BSA) for 48 h. Cells
were then treated with 10 lmol/L indoxyl sulfate in the
presence of 0.5% BSA in DMEM/F12 media. After 6 and
18 h of further incubation, cells were harvested and total
RNA was extracted using Ambion RNAqueous kits
(AM1912, Ambion, Life Technologies Australia Pty Ltd,
Mulgrave, Vic., Australia). Three independent experi-
ments were performed with triplicate samples in each
group.
RNA extraction
RNA was extracted using Qiagen RNeasy kits (Qiagen,
Hilden, Germany) from the viable myocardium of the
remote noninfarct region of the left ventricle (30 mg)
from MI rats. This region of the myocardium was chosen
because it receives even exposure to uremic toxins con-
centrations observed in the circulation. A similar region
of the heart was obtained for sham rats (Lekawanvijit
et al. 2013). Then cDNA synthesis was performed using
microRNA-specific primers (Applied Biosystems, Foster
City, CA), by method provided by the manufacturer.
Standard cDNA synthesis protocol was followed to obtain
cDNA for gene assays (Nankervis et al. 2013).
Quantitative PCR for microRNAs
Quantitative PCR experiments were performed using Taq-
Man assays (Applied Biosystems) by method described
previously (Szafranska et al. 2008). In brief, we added
10 ng total RNA, carried out reverse transcription in
duplicate (16°C for 30 min, 42°C for 30 min, 85°C for
5 min, and then to 4°C), and then conducted PCRs in
duplicate from each reverse transcription reaction (95°C
for 1 min and 40 cycles of 95°C for 15 sec and 60 °C for
30 sec). All PCR amplifications were performed on ViiA
7 Real-Time PCR system (Applied Biosystems) using ViiA
7 RUO Software. mRNA was normalized to U87 endoge-
nous control and the relative fold difference in expression
was calculated using the 2DDCt method (Wilkinson-Berka
et al. 2009).
Quantitative PCR for genes
Quantitative PCR experiments were performed using Taq-
Man assays (Applied Biosystems) by method described
previously (Nankervis et al. 2013). mRNA was normalized
to GAPDH endogenous control and the relative fold dif-
ference in expression was calculated using the 2DDCt
method (Wilkinson-Berka et al. 2009). All PCR amplifica-
tions were performed on ViiA 7 Real-Time PCR system
(Applied Biosystems) using ViiA 7 RUO Software. The
primer sequences used in the study are found in Table 1.
Western blot analysis
Noninfarcted myocardial tissue (30 mg) was homogenized
with 1 mL of modified RIPA buffer in the presence of
protease and phosphatase inhibitors. Equal amounts of
protein (30 lg) were separated by 10% sodium dodecyl
sulfate-polyacrylamide gel electrophoresis, and electropho-
retically transferred to nitrocellulose membranes (Amer-
sham Biosciences). Western blot analysis was performed
as per manufacturer’s protocol with collagen- I (Novus
Biologicals, Littleton, CO) and pan-actin antibody (Neo-
Markers, Fremont, CA) and then visualized by enhanced
chemiluminescence (Thermo Scientific, Rockford, IL).
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Band intensity was analyzed using ImageJ software (U.S.
National Institutes of Health, Bethesda, MD). Pan-actin
antibody was used to measure endogenous controls
proteins.
Quantitation of fibrosis
Four micron paraffin-embedded tissue sections from the
heart and kidney were stained with picrosirius red to
determine the level of fibrosis in sham and MI rats. Ten
random nonoverlapping fields from the remote noninfarct
cardiac regions and the renal cortex-to-corticomedullary
region (glomeruli excluded) of all animals were captured
using a microscope attached to a digital camera (Carl
Zeiss AxioVision, Germany). Fibrosis was evaluated by cal-
culating the proportional area of picrosirius red-stained
matrix using image analysis (AIS, Analytical imaging
Station Version 6.0, Imaging Research Inc, Ontario,
Canada).
Kidney injury molecule-1 (KIM-1) expression
Tissue expression of kidney KIM-1 was assessed by immu-
nohistochemistry (Lekawanvijit et al. 2013), using goat an-
tiKIM-1 (R&D systems, Minneapolis, MN, 1:200 dilution)
antibody. Numbers of KIM-1-positive tubules were
counted from whole kidney sections under a microscope.
Statistical analysis
Data are presented as mean  SEM. One-way ANOVA
with Bonferroni’s multiple comparison test or Kruskal–
Wallis test with Dunn’s multiple comparison test were
used for comparisons among all groups for parametric
and nonparametric data, respectively. For comparisons
between two groups, unpaired Student’s t-test was used
for parametric data and Mann–Whitney test for non-
parametric data. All statistical analyses were performed
using GraphPad Prism 5 (Version 6.04, La Jolla, CA).
The presence of correlations between variables was ana-
lyzed using Pearson’s correlation analysis.
Results
Serum IS levels
Compared to sham animals, the serum IS level at 16 weeks
was 38% higher in MI+Vehicle-treated rats (P < 0.05,
Table 1). Serum IS level in AST-treated MI rats was signif-
icantly lower compared to both sham and MI+Vehicle rats
Table 1. Cardiac and renal measurements from Sham, MI+Vehicle and MI+AST-120-treated animals. Data presented as mean  SEM.
Sham (n = 12) MI+Veh (n = 8) MI+AST-120 (n = 9)
Kidney data
Renal Interstitial Fibrosis (% area) 1.92  0.15 4.22  0.14*** 3.32  0.18***,##
Kim-1 Positive Renal Tubule 11.00  2.40 25.25  7.11* 6.56  1.97##
Glomerular Filtration Rate (mL/min/kg) 10.64  0.36 9.88  0.41 9.51  0.43
Indoxyl Sulfate Data
Serum Indoxyl Sulfate Levels 8 weeks (mg/dL) 0.18  0.02 0.21  0.01 0.04  0.01***,###
Serum Indoxyl Sulfate Levels 16 weeks (mg/dL) 0.18  0.02 0.25  0.03* 0.04  0.01***,###
Delta Serum Indoxyl Sulfate (IS) (mg/dL) 0.07  0.02 0.15  0.04* 0.10  0.02***,###
Cardiac Data
Systolic Blood Pressure (mmHg) 90.68  3.34 89.26  4.43 86.07  3.19
Diastolic Blood Pressure (mmHg) 62.36  3.11 63.84  4.92 62.56  3.08
Heart Rate (BPM) 275.75  14.28 279.38  9.78 292.44  17.23
Preload Recruitable Stroke Work (mmHg) 83.67  6.76 58.62  4.76** 69.35  6.55
Tau Logistic (msec) 9.64  0.29 13.42  0.93** 11.87  0.79*
Tau Weiss (msec) 12.87  0.38 16.97  0.87** 15.56  0.97*
LV End Diastolic Pressure (mmHg) 4.48  0.31 6.65  0.84* 6.53  0.57*
dP/dt max (mmHg/sec) 5636  163 4653  208** 4647  182**
dP/dt min (mmHg/sec) 5252  231 3458  179*** 3442  193***
Collagen I/Actin (Relative Protein expression) 0.10  0.02 0.63  0.09*** 0.11  0.06###
TGF-b1 mRNA (Fold Change Relative to Sham) 1.00  0.04 1.37  0.11** 0.91  0.072###
Cardiac Infarct Size (%) 0.0 41.63  3.47*** 44.61  52.89***
Fractional Shortening (%) 39.29  1.71 24.71  3.78** 20.40  2.54**
Left Ventricular Ejection Fraction (%) 66.41  1.82 40.31  5.22** 42.11  4.48**
*P < 0.05, **P < 0.01, ***P < 0.001 versus Sham. #P < 0.05, ##P < 0.01, ###P < 0.001 versus MI+Vehicle.
Data analyzed by performing one-way ANOVA followed by Bonferroni post hoc analysis.
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(P < 0.001 compared to MI+Veh, Table 1). Compared to
sham animals, the difference in serum IS levels before and
after treatment at 16 weeks, (Delta IS) were 2.5-fold higher
in MI+Vehicle rats (P < 0.05, Table 1). This was com-
pletely attenuated by AST-120 treatment (P < 0.001 com-
pared to MI+Veh, Table 1).
Cardio-renal fibrosis and cardiac function
data
Compared to sham animals, the percentage of renal fibro-
sis was increased 2.2-fold in vehicle-treated MI animals
(P < 0.001, Table 1). In AST-120-treated MI animals, the
percentage of renal fibrosis was significantly attenuated
compared to the vehicle MI group (P < 0.01) but was
higher compared to sham animals (P < 0.001, Table 1).
Compared to sham animals, expression of the renal injury
marker Kim-1 was 2.29-fold higher in vehicle-treated MI
animals (P < 0.05, Table 1). This increase in Kim-1
expression was attenuated by AST-120 treatment
(P < 0.01 compared to MI+Veh, Table 1). There was a
significant reduction in the percentage of left ventricular
fractional shortening and left ventricular ejection fraction
in vehicle-treated MI animals compared to sham animals
(P < 0.01). Reduction in the percentage of left ventricular
fractional shortening after MI was not different in AST-
120 treatment group compared to MI+Veh group of ani-
mals (P = 0.351, Table 1). Left ventricular infarct size was
similar in both MI groups (P < 0.001 compared to sham
for both, Table 1).
Picrosirius red staining in the heart was evident in all
three groups (Fig. 1A) but it was highest in vehicle-trea-
ted MI group. The percentage area of cardiac fibrosis was
significantly higher in vehicle MI group compared to
sham animals (P < 0.001, Fig. 1B). The AST-120-treated
MI group had significantly reduced cardiac fibrosis com-
pared to the vehicle MI group (P < 0.01, Fig. 1B).
Cardiac microRNAs
microRNA-21
There was twofold increase in microRNA-21 mRNA
expression in the noninfarct myocardium of the MI+Veh
group compared to sham animals (P < 0.01, Fig. 2A).
MicroRNA-21 mRNA expression level in MI+AST-120
group was significantly lower compared to the MI+Veh
group (P < 0.05, Fig. 2A).
A
B
Sham MI + Veh MI + AST
Figure 1. (A) Figure shows picrosirius red staining in heart from sham, MI+Vehicle and Mi+AST group of rats (B) Quantitative analysis of the
percentage area of cardiac fibrosis measured by picrosirius red staining. Data presented as meanSEM. ***P < 0.001 versus Sham. ##P < 0.01
versus MI+Vehicle. Data analyzed by performing a one-way ANOVA followed by Bonferroni post hoc tests.
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microRNA-29b
MicroRNA-29b mRNA expression in noninfarct myocar-
dium was reduced by 50% in the MI+Veh group
compared to sham animals (P < 0.01, Fig. 2B). MicroR-
NA-29b mRNA expression level in MI+AST-120 was
significantly higher compared to the MI+Veh group
(P < 0.001, Fig. 2B). There was no significant difference
between levels of microRNA-29b mRNA in the sham and
MI+AST-120 group (Fig. 2B).
Correlation between microRNA and IS
MicroRNA-21 mRNA levels were positively correlated
with serum IS levels in rats (P = 0.031; r2 = 0.16,
Fig. 2C). In contrast to microRNA-21, the microRNA-
29b mRNA levels were negatively correlated with serum
IS (r2 = 0.20; P = 0.014, Fig. 2D).
Cardiac mRNA for extracellular matrix
proteins and TGF- b1
Compared to sham, cardiac mRNA levels for extracellular
matrix proteins fibronectin-1 (P < 0.01, Fig. 3A) and col-
lagen 1 A1 (P < 0.01, Fig. 3B) were higher in the
MI+Veh group. This increase was significantly attenuated
by AST-120 treatment (Fig. 3A and B). TGF-b1 levels
were 37% higher in MI+Veh group compared to sham
(P < 0.01, Table 1). TGF-b1 levels were 51% lower in the
MI+AST-120 group as compared to the MI+Veh group
(P < 0.001, Table 1). There was no significant difference
between levels of TGF-b1 mRNA in sham and MI+AST-
120 groups.
Cardiac mRNA for Spry-1, PTEN and Smad 7
Compared to sham animals, Spry 1 mRNA expression
was 27% lower in MI+Veh group of rats (P < 0.05,
Fig. 4A). AST-120 treatment completely restored Spry 1
expression to similar levels observed in sham rats
(P < 0.05 vs. MI+Veh, Fig. 4A). Compared to sham
PTEN mRNA expression was 29% lower in MI+Veh
group but did not reach significance (P = 0.09, Fig. 4A).
Compared to sham, PTEN levels were 47% lower in
MI+AST-120 group of rats (P < 0.05, Fig. 4B), but they
were not significantly different from the MI+Veh group.
Cardiac Smad 7 mRNA expression was not different
between the three groups of animals (Fig. 4C).
Correlation between microRNA and target
genes
Cardiac microRNA-29b mRNA level was negatively corre-
lated with its target gene TGF-b1 (r2 = 0.19; P = 0.019,
A
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Figure 2. Quantitative analysis of (A) microRNA-21 and (B) microRNA-29b mRNA from sham (N = 12), MI+Vehicle (N = 8) and MI+AST-120
(N = 9) group of rats. Data presented as mean  SEM. **P < 0.01 versus Sham. #P < 0.05, ###P < 0.001 versus MI+Vehicle. Data analyzed by
performing a one-way ANOVA followed by Bonferroni post hoc tests. (C) microRNA-21 correlated with Indoxyl Sulfate (r2 = 0.16; P = 0.031;
two-tailed Pearson’s correlation test). (D) microRNA-29b correlated with Indoxyl Sulfate (r2 = 0.20; P = 0.014; two-tailed Pearson’s correlation
test).
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Fig. 3C). MicroRNA-29b levels were negatively and signif-
icantly correlated with its target genes collagen 1A1
(r2 = 0.27; P = 0.005, Fig. 3D) and fibronectin-1
(r2 = 0.17; P = 0.03, Fig. 3E). Also, cardiac microRNA-21
mRNA level was positively correlated with cardiac TGF-
b1 (r2 = 0.17; P = 0.032; Fig. 3F).
Cardiac collagen 1 protein levels
Cardiac collagen 1 protein levels were increased sixfold in
vehicle-treated MI rats compared with sham animals
(P < 0.001, Table 1). This increase in MI-induced colla-
gen 1 protein was completely attenuated by AST-120
treatment (P < 0.001 compared with MI+Veh, Table 1).
Collagen 1 protein levels in AST-120-treated MI rats were
not different to sham rats. There was a significant positive
correlation between collagen I protein levels and collagen
1A1 mRNA (r2 = 0.25; P = 0.018, Data not shown).
Cardiac ACE and Agtr1a mRNA expression
Compared to sham animals, cardiac mRNA levels for
ACE were 65% higher in the MI+Veh group (P < 0.05,
Fig. 5A). Agtr1a mRNA levels were 59% higher in
MI+Veh group when compared with sham animals
(P < 0.05, Fig. 5B). These increases in ACE and Agtr1a
mRNA expression were significantly attenuated by AST-
120 treatment (Fig. 5A and B).
Cardiac Smad 3 and Smad 4 mRNA
expression
Cardiac Smad 3 levels were not different between any of
the three groups of animals studied (Fig. 5C). Compared
to the sham group, there was 36% increase in cardiac
Smad 4 mRNA levels (P < 0.01, Fig. 5D). This increase in
Smad 4 expression was significantly attenuated by AST-
120 treatment (P < 0.05, Fig. 5D).
Direct IS activation of microRNA and
profibrotic signaling in primary cardiac
fibroblasts
After 18 h of IS treatment, cardiac fibroblasts demon-
strated a 60% increase in microRNA-21 mRNA expres-
sion, and a 68% decreased expression of microRNA-29b
mRNA (P < 0.05 for both, compared to control, Fig. 6A
and B). Similar trends were observed following 6 h of IS
treatment but these were not significantly different from
control (Fig. 6A and B).
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mRNA expression of all three profibrotic genes fibro-
nectin-1, collagen 1A1, and TGF-b1 were significantly
higher after 18 h of IS treatment (P < 0.01 for all three
genes, compared to control, Fig. 7A–C). Only collagen 1
A1 had significantly higher mRNA expression as early as
6 h after IS treatment (P < 0.01, compared to control,
Fig. 7B). Expression of Spry 1 was significantly lower in
cells treated with IS for 18 h (P < 0.05, Fig. 8A). PTEN
and Smad 7 mRNA expression were not different to con-
trol at any of the treatment times (Fig. 8B and C).
Expression of ACE was significantly higher in cells treated
with IS for 18 h (P < 0.05, Fig. 9A). Agtr1a mRNA
expression was 25% higher after 18 h of IS treatment,
however, this did not attain significance (Fig. 9B). Com-
pared to control, both Smad 3 and Smad 4 mRNA were
significantly higher at 18 h after IS treatment (P < 0.05
for Smad 3 and P < 0.01 for Smad 4, Fig. 9C and D).
Discussion
This is the first study to report the regulation of cardiac
microRNAs (21 and 29b) together with inhibition of
fibrosis in the myocardium of MI rats after lowering ure-
mic toxins levels. We report that exposure to elevated
serum IS causes an increase in microRNA-21 mRNA
expression along with reduced mRNA expression of micr-
oRNA-29b in the heart. We report a significant correla-
tion between cardiac microRNA-21 and serum IS, and a
significant but inverse association between cardiac micr-
oRNA-29b and serum IS. These two microRNAs govern
cardiac fibrosis through their ability to regulate the fibro-
tic actions of TGF-b1, a key mediator of cardiac fibrosis.
Furthermore, activation of the angiotensin system was
observed in vivo with increased gene expression of Agtr1a
and ACE. Treatment with AST-120 inhibited cardiac
fibrosis, ACE, Agtr1a, Smad 4, microRNA-21 expression
and restored cardiac microRNA-29b mRNA expression
toward Sham levels suggesting activation of the cardiac
renin-angiotensin system as a mechanism for altering mi-
croRNAs expression by uremic toxins such as IS.
Expression of microRNAs (21 and 29b) in the heart
post-MI has been previously determined. van Rooij et al.
(2008) reported reduced microRNA-29b in peri-infarct
and remote myocardium within 3 days of MI induction,
which was still significantly lower in peri-infarct but not
in remote myocardium at 2 weeks post-MI. Earlier stud-
ies in rodent models have reported altered expression of
microRNA-21 within the first 2 weeks after induction of
MI (Dong et al. 2009; Liang et al. 2012).
Neonatal cardiac cells were used in this study since
they are a proven model of cardiac fibrosis and are useful
for evaluating the efficacy of therapeutic agents (Thomas
et al. 2002a,b; Woodcock et al. 2002) Neonatal cardiac
cells also express the fetal gene program which is reex-
pressed in adult cells and tissues with heart failure
(Woodcock et al. 2002; Taegtmeyer et al. 2010). Given
that chronic left ventricular dysfunction, in an MI model
is known to cause pathological fibrosis with regulatory
effects on miRNAs, we sought to determine whether IS, a
profibrotic molecule, could regulate these miRNAs in car-
diac fibroblast culture. Our fibroblasts data with IS treat-
ment demonstrate a clear role for IS in altering
expression of these microRNAs and their target genes
mimicking the in vivo data. The in vitro cardiac fibroblast
data showed increased collagen IA1 following IS stimula-
tion but not fibronectin or TGFb1 gene expression at the
earlier time point of 6 h, this may be due to the effects of
IS on pathways other than TGFb1. We have previously
reported IS-mediated increases in nuclear factor kappaB
activation in neonatal cardiac fibroblasts (Lekawanvijit
et al. 2010) which may be a result of increased reactive
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oxygen species that induces collagen synthesis. Subse-
quently IS may induce fibrotic genes such as TGFb1 and
fibronectin at the later time point investigated in this
study. Further investigation over several time points needs
to be performed to clarify the involvement of these path-
ways.
The dose of IS in our cell culture experiments is
equivalent to the concentration of IS measured in the
serum of vehicle-treated MI animals at 16 weeks. Our
animal data suggest that AST-120 treatment prevented
uremic toxin-induced attenuation of cardiac microR-
NAs-29b post-MI, leading to significant downregulation
of microRNA-29b target genes TGF-b1, collagen 1A1
and fibronectin-1. Studies have shown that overexpres-
sion of microRNA-29b in cardiac fibroblasts prevents
the angiotensin II-mediated increase in collagen 1
mRNA and protein (Zhang et al. 2014). MicroRNA-29
overexpression and knockdown studies in cardiac cells
and other cell types have reported its inhibitory action
on the TGF-b1 pathway (Cushing et al. 2011; Luna et al.
2011; Roderburg et al. 2011; Zhang et al. 2014). MicroR-
NA-29b directly binds to exon 3 coding sequence for
TGF-b1 to promote its mRNA degradation and inhibit
its translation (Zhang et al. 2014). TGF-b1 can also
inhibit microRNA-29b expression by activating the Smad
signaling pathway (Qin et al. 2011; Winbanks et al.
2011; Xiao et al. 2012; Zhang et al. 2014). Collectively,
these findings suggest the presence of a negative recipro-
cal loop between TGF-b1 and microRNA-29b, where
activation of one leads to inhibition of the other. Our
results suggest that uremic toxins modulate this loop
favoring inhibition of microRNA-29b and promoting
cardiac fibrosis.
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The profibrotic cytokine TGF-b1 is a key regulator of
fibrosis in cardiac fibroblasts (Youn et al. 1999; Bujak and
Frangogiannis 2007). Fibrotic pathways activated by TGF-
b1 involve increased cardiac synthesis of ECM proteins
fibronectin and collagens (I-III) (Eghbali et al. 1991; Hei-
mer et al. 1995; Villarreal et al. 1996), their accumulation
in the myocardium has been reported following MI (See-
land et al. 2002; van Dijk et al. 2008; Dworak et al. 2012;
Lekawanvijit et al. 2013). Excessive collagen and ECM
protein deposition in the heart are known to cause
arrhythmia, mechanical stiffness, disorganized contrac-
tion, and hypoxia, which ultimately contribute to the
development of heart failure. Studies on pathologies of
the heart, kidney, and lung involving fibrosis have
reported altered expression of microRNA-21 and microR-
NA-29b along with increased expression of TGF-b1
(Thum et al. 2008; Cushing et al. 2011; Qin et al. 2011;
Roderburg et al. 2011; Noetel et al. 2012; Patel and
Noureddine 2012; Xiao et al. 2012; Wang et al. 2013a,b).
It is well established that the TGF-b1 signaling pathway
is regulated by intracellular signaling proteins known as
Smads which play an important role in fibrosis. Increased
protein levels of Smad 2, 3, and 4 have been reported in
cardiac scar and border tissue collected from rats 8 weeks
after MI (Hao et al. 1999). TGF-b1 binds to its cell sur-
face receptors and phosphorylates Smad 2 and Smad 3
(also known as R-Smad) which form a bond with Smad 4
(also known as co-Smad) in the cytoplasm. This complex
translocates to the nucleus where it binds to the promoter
region of microRNAs and TGF-b1 target genes to modu-
late their expression (Tang and Lan 2014). Our results
show increased cardiac mRNA expression of Smad 4 but
not Smad 3 in vehicle-treated MI rats. Inhibition of this
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increase in Smad 4 by AST-120 treatment, and upregula-
tion Smad 3 and Smad 4 expression in IS-treated cardiac
fibroblast cells, suggest Smads are involved in IS-mediated
alteration of cardiac microRNAs and profibrotic gene
expression. The role of Smads in the kidney has been well
documented in renal fibrosis which may help explain our
findings in the heart. Smad3-deficient mice are protected
from renal tubulointerstitial fibrosis in the unilateral ure-
teral obstruction model (Zhong et al. 2011), and inhibi-
tion of Smad4 expression by siRNAs in mice significantly
inhibited renal fibrosis induced by folic acid (Morishita
et al. 2014). A recent study using Smad 4 knockout mice
has reported attenuation of renal fibrosis in a unilateral
ureteral obstruction model (Meng et al. 2012). Thus, our
data indicate that the inhibition of Smad 4 mRNA by
lowering serum IS levels, appears to be a mechanism for
the inhibition of fibrosis.
Angiotensin II is an important neurohormone that also
plays a pathogenic role in cardiac remodeling post-MI,
and is known to stimulate the synthesis and secretion of
TGF-b1 (Sharma et al. 1994; Yang et al. 2009) and acti-
vate the Smad pathway (Rodriguez-Vita et al. 2005) (Sun
et al. 1998) via either or both, TGF-b1 and/or p38/extra-
cellular signal-regulated kinase/mitogen-activated protein
kinase (p38/ERK/MAPK) pathways (Rodriguez-Vita et al.
2005; Yang et al. 2009). Our results showing increased
cardiac ACE expression after MI and IS treatment in
cardiac fibroblasts indicate that IS may upregulate local
angiotensin II signaling in cardiac cells to increase
TGF-b1 expression. Angiotensin II is already known to
upregulate TGF-b1 expression via activation of the Agtr1
receptors in cardiac cells mediating cardiac fibrosis (Ro-
senkranz 2004; Dobaczewski et al. 2011). The Agtr1
receptor antagonist losartan has been shown to inhibit
protein expression of both Smad 4 and the active form of
TGF-b1 in scar tissue from MI rats (Hao et al. 2000).
Therefore, our results demonstrating inhibition of Agtr1a
expression in AST-120-treated rats, compared with vehicle
MI rats, suggest that activation of Agtr1a receptors by
uremic toxins may be responsible for the increase in
Smad 4 mRNA expression.
Angiotensin II also has been reported to regulate
expression of microRNA-29 via Smads. Chronic angioten-
sin II infusion in wild-type mice resulted in significant
reduction in microRNA-29 while in Smad3 knockout
mice this reduction was prevented (Zhang et al. 2014). In
addition, overexpression of microRNA-29b in mice
prevented angiotensin II-induced cardiac fibrosis, and
inhibited TGF-b1, Smad 3 activation, and reduced
phosphorylation of ERK1/2 kinases. Furthermore, the
increased Agtr1a and decreased microRNA29b post-MI
and their reversal following AST-120 treatment may
involve elements of R-Smad.
Increased microRNA 21 expression in cardiac fibro-
blasts from failing heart has previously been reported,
and this augments ERK-MAP kinase activity through
inhibition of Spry1 8. In addition, angiotensin II treat-
ment of cardiac fibroblasts has previously been reported
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to increase microRNA-21 expression and decrease Spry1
expression (Adam et al. 2012). Here, we report a signifi-
cant reduction in the cardiac expression of microRNA-
21’s target gene Spry1 in vehicle-treated MI rats, and in
IS-treated cardiac fibroblast cells. In vivo silencing of
microRNA-21 in a pressure-overload model reduced car-
diac ERK-MAP kinase activity, inhibited interstitial fibro-
sis and attenuated cardiac dysfunction (Thum et al.
2008). PTEN and SMAD 7 are also direct targets for
microRNA-21, and an increase in microRNA-21 expres-
sion has an inhibitory effect on their expression. IS treat-
ment in cardiac fibroblasts did not have any effect on
mRNA expression of these genes despite significant
increases in expression of microRNA-21. Although, we
did observe a nonsignificant reduction in PTEN mRNA
expression in vehicle-treated MI rats, AST-120 treatment
did not restore their expression, suggesting involvement
of mechanisms independent of uremic toxins.
AST-120 reduced cardiac fibrosis in MI animals with-
out an improvement in cardiac function. Fibrosis in the
noninfarcted region, although increased in vehicle-treated
animals is still small in comparison to the injured
infarcted area which is normally 10 times greater. Hence
a small reversal of fibrosis (<2% Fig. 1) in the noninfarct-
ed region may not significantly contribute to the overall
function of the heart. Additionally a period longer than
16 weeks post-MI may be required to see improvements
in functional outcomes as the function deteriorates fur-
ther in MI+Veh-treated rats more than that of the AST-
120-treated rats.
We opted not to administer uremic toxins into non-
operated animals, since their normal renal function
would likely cause these toxins to be excreted in urine
without impacting on the kidney or the heart. Studies
have shown that in models of significantly impaired
renal function, have demonstrated using a chronic renal
Myocardial infarction  
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sulphate) 
Alters cardiac expression of 
target genes associated with 
fibrosis 
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Upregulate renin 
angiotensin system  
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Figure 10. Diagram outlines hypothesis and key findings of this study.
2015 | Vol. 3 | Iss. 4 | e12371
Page 12
ª 2015 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
the American Physiological Society and The Physiological Society.
MicroRNA Mediates Uremic Toxin-Induced Cardiac Fibrosis I. Rana et al.
injury model, addition of uremic toxins such as indoxyl
sulfate results in addition worsening of glomerulosclero-
sis, fibrosis, and reduced function (Niwa and Ise 1994;
Niwa 2013).
Measurement of Smad 3 and 4 phosphorylation levels
may provide more information in future studies regarding
the regulation of microRNA 21 and 29b-mediated fibro-
sis. In summary, as outlined in Fig. 10 our study provides
evidence that elevated IS levels caused by renal damage
secondary to MI has a direct effect of on the expression
of microRNA-21 and microRNA-29. This altered cardiac
microRNA expression after MI in turn increases the
expression of TGF-b1 and leads to cardiac fibrosis in the
myocardium. These findings suggest that treatments tar-
geting microRNA-21 and microRNA-29b may be a poten-
tial therapy for fibrosis in MI patients with concomitant
chronic kidney disease.
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